Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139459 · ClinicalTrials.gov registry record
Sepsis Characterization in Kilimanjaro
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 499
- Enrollment target
NCT05139459: Completed study, sponsored by Duke University.
NCT05139459 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 499 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139459 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 499 participants
- Enrollment target
Study Summary
The aim of this study is to prospectively evaluate the barriers to care, evaluation, clinical practices, and outcomes for patients presenting with sepsis to hospitals in the Kilimanjaro Region of northern Tanzania. This will include an assessment of timing and selection of antimicrobials and administration and volume of intravenous fluids. The study also aims to characterize sepsis sub-types in the epidemiologic context of northern Tanzania using statistical clustering techniques of clinical variables and of host immune response patterns.
Primary Outcome
Number of sepsis subtypes identified by statistical clustering analysis of clinical characteristics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 499 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2023-11-03 |
What the finished NCT05139459 record still lists
NCT05139459 is an observational study that tracks outcomes without assigning an intervention. The registered 499 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05139459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05139459 about?
NCT05139459 is a clinical study titled "Sepsis Characterization in Kilimanjaro". The aim of this study is to prospectively evaluate the barriers to care, evaluation, clinical practices, and outcomes for patients presenting with sepsis to hospitals in the Kilimanjaro Region of northern Tanzania. This will include an assessment of timing and selection of antimicrobials and adminis...
What is the current status of trial NCT05139459?
This trial is currently completed. The enrollment target is 499 participants. The study started on 2022-01-17. Estimated completion is 2023-11-03.
Who is sponsoring clinical trial NCT05139459?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI